Mount Yale Investment Advisors LLC Has $1.27 Million Stock Holdings in Boston Scientific Co. (NYSE:BSX)

Mount Yale Investment Advisors LLC lowered its stake in Boston Scientific Co. (NYSE:BSX - Free Report) by 15.5% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 14,187 shares of the medical equipment provider's stock after selling 2,607 shares during the period. Mount Yale Investment Advisors LLC's holdings in Boston Scientific were worth $1,267,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the company. Susquehanna Fundamental Investments LLC bought a new position in shares of Boston Scientific during the second quarter worth about $2,273,000. Kathmere Capital Management LLC acquired a new position in Boston Scientific during the 2nd quarter valued at about $201,000. Ascent Group LLC raised its position in shares of Boston Scientific by 11.8% during the 2nd quarter. Ascent Group LLC now owns 7,480 shares of the medical equipment provider's stock worth $576,000 after buying an additional 790 shares in the last quarter. Creative Planning lifted its stake in shares of Boston Scientific by 13.7% in the 2nd quarter. Creative Planning now owns 189,545 shares of the medical equipment provider's stock worth $14,597,000 after acquiring an additional 22,901 shares during the period. Finally, NewEdge Advisors LLC increased its stake in shares of Boston Scientific by 34.0% during the second quarter. NewEdge Advisors LLC now owns 81,307 shares of the medical equipment provider's stock valued at $6,261,000 after acquiring an additional 20,644 shares during the period. Institutional investors and hedge funds own 89.07% of the company's stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on BSX. Citigroup lifted their price target on Boston Scientific from $98.00 to $107.00 and gave the company a "buy" rating in a research report on Wednesday, December 11th. JPMorgan Chase & Co. increased their price target on Boston Scientific from $100.00 to $110.00 and gave the company an "overweight" rating in a research report on Monday, December 16th. Deutsche Bank Aktiengesellschaft upgraded shares of Boston Scientific from a "hold" rating to a "buy" rating and set a $108.00 target price for the company in a report on Friday, January 10th. Stifel Nicolaus lifted their target price on shares of Boston Scientific from $85.00 to $100.00 and gave the stock a "buy" rating in a research report on Friday, October 18th. Finally, Truist Financial lifted their price objective on shares of Boston Scientific from $100.00 to $110.00 and gave the stock a "buy" rating in a research report on Wednesday, December 18th. Three investment analysts have rated the stock with a hold rating, twenty have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Boston Scientific presently has an average rating of "Moderate Buy" and a consensus price target of $97.26.

Insider Buying and Selling

In other Boston Scientific news, EVP Arthur C. Butcher sold 14,010 shares of the stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $89.27, for a total transaction of $1,250,672.70. Following the sale, the executive vice president now owns 978 shares of the company's stock, valued at $87,306.06. This represents a 93.47 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Edward J. Ludwig sold 4,877 shares of the company's stock in a transaction on Thursday, November 21st. The stock was sold at an average price of $91.63, for a total value of $446,879.51. Following the transaction, the director now directly owns 39,398 shares in the company, valued at approximately $3,610,038.74. This represents a 11.02 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 29,989 shares of company stock worth $2,702,261 in the last 90 days. 0.50% of the stock is owned by company insiders.

Boston Scientific Stock Performance

BSX stock traded up $0.14 on Tuesday, reaching $102.41. 7,904,976 shares of the company were exchanged, compared to its average volume of 5,928,015. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.48 and a quick ratio of 1.02. Boston Scientific Co. has a 12 month low of $60.78 and a 12 month high of $102.93. The stock's fifty day moving average price is $92.50 and its 200 day moving average price is $85.63. The firm has a market capitalization of $150.93 billion, a PE ratio of 84.63, a PEG ratio of 2.63 and a beta of 0.80.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.